Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kos Pharmaceuticals, Inc (KOSP) -- Ignore unavailable to you. Want to Upgrade?

To: Michael Young who wrote (37)	2/3/1998 9:16:00 AM
From: Michael Young	Read Replies (1) \| Respond to of 118

Niaspan prescriptions looking strong. On a pace to be up 60% in January vs. December. MIKE

To: Michael Young who wrote (37)	3/5/1998 12:09:00 PM
From: JerryR	Read Replies (2) \| Respond to of 118

From two analysts, dated earlier this year: Cowen, on a downgrade to neutral, expected Q4 to be (0.90) and FY97 to be (2.75). They also predicted the sales of Niaspan for Q4:97 and Q1:98 to be in line with Q3:97. Further out they suggest the market share in 2001 to be 1% of the 16B cholesterol market. Also, KOSP may need additional financing before it gets in the black which may be in 2000. (1998: loss of $3.20 and 1999: loss of $0.85). Warburg Dillon called for a Q4:97 loss of 0.82 and a FY97 loss of 2.67. As of the beginning of the year they seemed more positive, predicting black ink as early as Q3:98, and a FY98 at a +0.03. SG&A and R&D should continue to grow through 1998. Gross margins should continue to be in the 80% range. Kosp has 7 products in development, primarily in the respiratory (asthma) and cardiovascular markets. Results, if any, will be distant. Earnings were released yesterday: Q4:97: (0.89) and FY 97: (2.79). P.S.:The above may be erroneous. Jerry